ReviewMaterials today. Bio2025
Multifunctional nanotherapeutics reprogramming the immunopathological landscape for rheumatoid arthritis therapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modulation of innate and adaptive immunity by pH-responsive nanozyme-like nanoparticles with high mobility for rheumatoid arthritis alleviation.Bioactive materials · 2026Article
- Physicochemically-guided immunomodulatory biomaterials for regulating immune responses in rheumatoid arthritis.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a prototypical and highly prevalent form of autoimmune disease, rheumatoid arthritis (RA) serves as a valuable model for elucidating pathogenic mechanisms and developing targeted and functional nanomedicines. Emerging research not only offers promising alternatives for RA patients that are incompatible with conventional disease-modifying antirheumatic drugs (DMARDs), but also inspires the engineering of innovative nanomedicines via interdisciplinary science and technology. This review presents a comprehensive overview of the immunopathological landscape of RA, emphasizing the key players in disease development and progression, including fibroblast-like synoviocyte, macrophage, lymphocyte and neutrophil, and delineates how these pathogenic processes create opportunities for targeted intervention. We highlight cutting-edge advances in microneedle-enhanced transdermal delivery, intelligent polymeric biomimetic targeting systems and multifunctional composite platforms. Furthermore, we explore critical developmental pathways for potential clinical translation by employing precision targeting strategies, advancing co-delivery technologies and integrating diagnostics with therapeutics. Collectively, these perspectives offer significant insights for refining precision treatment paradigms in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.